Actinium Pharmaceuticals
ATNM
36 hedge funds and large institutions have $15.9M invested in Actinium Pharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 17 increasing their positions, 4 reducing their positions, and 4 closing their positions.
325% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 4
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
6% more funds holding
Funds holding: 34 → 36 (+2)
0.02% less ownership
Funds ownership: 0.32% → 0.3% (-0.02%)
12% less capital invested
Capital invested by funds: $18M → $15.9M (-$2.15M)
96% less call options, than puts
Call options by funds: $2K | Put options by funds: $46K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$554K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
+$491K |
| 3 |
TC
TFS Capital
West Chester,
Pennsylvania
|
+$418K |
| 4 |
Morgan Stanley
New York
|
+$228K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$119K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.95M |
| 2 |
SG Americas Securities
New York
|
-$77K |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$70.8K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$42.7K |
| 5 |
PP
Patten & Patten
Chattanooga,
Tennessee
|
-$15.9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Citigroup
New York
| $21K | +$18.2K | +96 | +384% |
|
27
Canada Life
Winnipeg,
Manitoba, Canada
| $8K | +$7.59K | +40 | +1,333% |
|
28
UBS Group
Zurich,
Switzerland
| $8K | +$8.93K | +47 | New |
|
29
AllianceBernstein
Nashville,
Tennessee
| $6K | – | – | – |
|
30
Wells Fargo
San Francisco,
California
| $6K | – | – | – |
|
|
WCM
31
Westend Capital Management
Sausalito,
California
| $6K | – | – | – |
|
32
Barclays
London,
United Kingdom
| $6K | +$6.27K | +33 | +471% |
|
33
Creative Planning
Overland Park,
Kansas
| $5K | +$5.13K | +27 | New |
|
|
MA
34
MUFG Americas
New York
| $4K | +$2.09K | +11 | +79% |
|
|
LTFS
35
Ladenburg Thalmann Financial Services
Miami,
Florida
| $3K | +$3.42K | +18 | New |
|
36
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $90 | +$7.97K | +42 | +9% |
|
|
SFM
37
Sphera Funds Management
Tel Aviv,
Israel
| – | -$1.95M | -9,710 | Closed |
|
|
38
SG Americas Securities
New York
| – | -$77K | -381 | Closed |
|
39
BNP Paribas Financial Markets
Paris,
France
| – | -$9.15K | -46 | Closed |
|
40
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$1.52K | -8 | Closed |
|
ATNM Hedge Fund Activity: Q4 2014 in Review
36 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q4 2014, worth a combined $15.9M — down 12% from $18M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new ATNM positions and 4 closed out — a net gain of 2 holders — while 17 added to existing stakes and 4 trimmed.
The largest buyer was BlackRock Fund Advisors, adding an estimated $554K. The largest seller was Sphera Funds Management, exiting entirely with an estimated $1.95M sold.
- 36 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q4 2014, up from 34 in Q3 2014.
- Funds reported $15.9M of Actinium Pharmaceuticals stock for Q4 2014, down 12% quarter-over-quarter.
- 6 funds opened new Actinium Pharmaceuticals positions in Q4 2014 and 4 closed out, a net change of +2 holders.
- The largest Actinium Pharmaceuticals buyer in Q4 2014 was BlackRock Fund Advisors, an estimated $554K added.
- The largest Actinium Pharmaceuticals seller in Q4 2014 was Sphera Funds Management, an estimated $1.95M sold.
Based on aggregated 13F filings for Q4 2014.